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Fibrates, the PPARa ligand-like compounds increase the
expression of proximal tubule liver fatty acid binding protein
(L-FABP) and significantly decrease cisplatin-induced acute
kidney injury. To study whether the bezafibrate-mediated
upregulation of renal L-FABP was involved in this
cytoprotective effect we treated transgenic mice of PPAR
agonists inducible human L-FABP expression with cisplatin in
the presence or absence of bezafibrate. Blood urea nitrogen
was unchanged in the first day but increased 3 days after
cisplatin. While urinary L-FABP increased over 100-fold 1 day
after cisplatin treatment in the transgenic mice it was
significantly reduced when these transgenic mice were
pretreated with bezafibrate. Cisplatin-induced renal necrosis
and apoptosis were significantly reduced in bezafibrate
pretreated transgenic mice and this correlated with
decreased accumulation of lipid and lipid peroxidation
products. Immunohistochemical analysis of kidney tissue of
bezafibrate-cisplatin-treated transgenic mice showed
preservation of cytoplasmic L-FABP in the proximal tubule,
but this was reduced in transgenic mice treated only with
cisplatin. L-FABP mRNA and protein levels were significantly
increased in bezafibrate-cisplatin-treated transgenic mice
when compared to mice not fibrate treated. Our study shows
that the bezafibrate-mediated upregulation of proximal
tubule L-FABP plays a pivotal role in the reduction of
cisplatin-induced acute kidney injury.
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The intracellular fatty acid-binding proteins (FABPs) belong
to a superfamily of lipid-binding proteins with low molecular
weight (14–15 kDa), which are classified according to their
predominant tissue localization. Nine different FABPs have
been reported with tissue-specific distribution that includes
L (liver), I (intestinal), H (muscle and heart), A (adipocyte),
E (epidermal), Il (ileal), B (brain), M (myelin), and
T (testis).1 All FABPs bind to long-chain fatty acids. However,
binding affinity and ligand selectivity are different for each
isoform.2 The L-type of FABP (L-FABP) is highly expressed
in hepatocytes, where it represents 5% of the total cytosolic
protein. In the human kidney, L-FABP is predominantly
expressed in proximal tubules. L-FABP facilitates the cellular
uptake, transport, and metabolism of fatty acids, and it is also
involved in the regulation of gene expression and cell
differentiation.3–5 A previous report demonstrated that
4-hydroxy-nonenal, a cytotoxic a,b-unsaturated acyl alde-
hyde resulting from lipid peroxidation in response to
oxidative stress, was able to bind E-FABP.6 Similarly, Wang
et al.7 showed in vitro the protective role of L-FABP in
reducing oxidative stress in hypoxia–reoxygenation. More
recently, Yamamoto et al.8 demonstrated that urinary L-FABP
behaved as a sensitive biomarker in response to ischemic
stress in human kidney transplantation. In addition, they
show that human transgenic (Tg) L-FABP mice have less
tubular injury during ischemia–reperfusion and intracellular
oxidative stress.8 These studies suggest that L-FABP not only
participates in fatty acid trafficking but also serves as an early
indicator of ischemic conditions and as a crucial cellular
antioxidant molecule.
Recent work also suggests that L-FABP is a member of the
lipocalin superfamily, which under normal conditions resides
in the lysosomal compartment of the proximal tubule, but
can also be reabsorbed from the glomerular filtrate via
megalin, a multiligand proximal tubule endocytic receptor.9
Cisplatin (CP)-induced acute kidney injury (AKI) is a
well-studied model of nephrotoxicity in rodents. The most
susceptible part of the kidney injured by CP is the S3 segment
of the proximal tubule. Tubular damage by CP is dose
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dependent. Kidney injury is rather mild when mice receive
o10 mg kg1 compared to 410 mg kg1. The mortality rate
increases remarkably when mice receive 20 mg kg1: renal
injury is more extensive, and mice do not survive more than
5 days. Hishikawa et al.10 tried to determine the marginal
dosage of CP that shows reasonably severe renal damage and
enables survival of more than 4 days, and they concluded that
the dose needed was 12.5 mg kg1. For this study, 20 mg kg1
was used to examine the efficacy of bezafibrate (Bz) to
ameliorate lethally induced injury by CP.
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors that involve various regulations of lipid
and glucose metabolism, adipogenesis, and inflammation.11
Three different isotypes of PPAR family have been identified:
PPAR-a, PPAR-b, and PPAR-g. All of these isotypes of PPARs
are known to reside in the kidney. PPAR-a and PPAR-g are
nuclear receptors that, besides being concerned with the
control of fatty acids and glucose metabolism, display anti-
inflammatory capabilities.2 PPAR-a exists in renal proximal
tubules and, subsequent to its activation by the ligand,
heterodimerizes with retinoic X receptor RXR, and regulates
gene transcription by binding to PPAR response elements
located in the regulatory regions of target genes. In a previous
study, Portilla and co-workers demonstrated that the efficacy
of fibrate, a known PPAR-a ligand, administered before AKI,
prevented the inhibition of fatty acid oxidation and
accumulation of non-esterified fatty acid in renal tissue
caused by CP and that it further ameliorated apoptotic and
necrotic proximal tubule cell death. That administration
resulted in significant protection of renal function only in
PPAR-a wild-type (WT) mice and not in PPAR-a null
mice.12–14 Recently, quantitative immunofluorescent analysis
revealed that a PPAR-a ligand-like fibrate increases the
expression of peroxisomal proteins in mouse kidney tissue.
A recent study suggests that increased expression of the
proximal tubule L-FABP, using a PPAR-a ligand-like fibrate,
ameliorates CP-induced AKI.15 This study further intends
to elucidate the involvement of L-FABP in Bz-induced
protection against CP-induced AKI using human L-FABP
(hL-FABP) Tg mice.
L-FABP is not normally expressed in mouse kidney tissue
unless mice are treated with fibrates; however, higher levels of
L-FABP protein expression are found in human proximal
tubules.8,16,17 Therefore, it is difficult to conduct renal in vivo
experiments using WT mice to examine the role of L-FABP in
AKI. For practical purposes, WT mice of the C57BL/6 strain
are considered as an example of naturally occurring renal
L-FABP-knockout mice. We recently developed hL-FABP Tg
mice in which the promoter region of hL-FABP was
overexpressed in C57BL/6. Therefore, the distribution of
L-FABP was similar to that in humans and suitable for
translational research of this protein. In addition, we have
developed an enzyme-linked immunosorbent assay system
for hL-FABP, which does not cross-react with rodent
L-FABP.18–20 The combination of hL-FABP Tg and hL-FABP
enzyme-linked immunosorbent assay has been used as novel
tool to examine the role of this biomarker in a wide variety of
human renal diseases. The results of this study (1) underscore
the protective role of Bz in reducing CP-induced AKI, (2)
elucidate the role of renal L-FABP in Bz-mediated cytopro-
tection, and (3) demonstrate the potential use of urinary
hL-FABP in the early diagnosis of CP-mediated AKI.
RESULTS
Time course of CP and fibrate on renal function
Animals were injected with either CP at a dose of 20 mg per
kg body weight or saline. Bz was fed for 1 week before CP
administration. Blood was drawn serially from each animal
up until 72 h after CP administration. Figure 1a presents the
dynamics of blood urea nitrogen (BUN). The remarkable
increase of BUN found after 48 and 72 h in CP-treated WT
mice (61.5±10.5 and 143.4±9.4, respectively; n¼ 9) was not
improved using Bz pretreatment in these animals (BzþCP,
53.4±8.3 and 149.2±12.9, respectively; n¼ 9). Figure 1b
depicts the dynamics of BUN in hL-FABP Tg mice. The levels
of BUN found after 48 and 72 h in CP-treated Tg mice
(58.3±4.0 and 135.5±7.3, respectively; n¼ 13) were equiva-
lent to those of CP-treated WT mice. Renal function
estimated as changes in BUN was significantly ameliorated
in Bz-pretreated Tg mice (48 h; BzþCP, 31.7±3.3 and 72 h;
61.6±6.9, respectively; Po0.05, n¼ 14).
Acute tubular damage and apoptosis
Histological analysis of CP-treated WT (Figure 2a),
CP-treated Tg (Figure 2b), and WT mice that had been fed
Bz (Figure 2c) revealed similar severity of acute tubular
damage at 72 h after administration of CP. In addition,
CP-treated Tg kidney (72 h after administration) showed the
same level of severity of acute tubular damage as did WT
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Figure 1 |Time course of BUN. Mice were fed with either a
regular diet or a diet containing 0.5% Bz for 7 days before CP
administration, as described in Materials and Methods. BUN levels
were measured at 24, 48, and 72 h after saline control (control)-,
CP (CP)-, BzþCP (CP pre-fed with Bz)-, and Bzþ saline (Bz with
saline)-treated mice. Bars correspond to means±s.e.m. of at least
seven independent experiments under each condition. Changes
in BUN levels are shown after saline or CP administration in (a) WT
and (b) hL-FABP Tg mice, respectively. Statistically significant
differences (*Po0.05, **Po0.05) were indicated when group data
were compared to control group data, and when BzþCP group
data were compared to data of the CP-alone group.
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kidney in terms of tubular dilatation, cast formation, brush-
border loss, and detachment of epithelial cells (Figure 2b). In
contrast, Bz pretreatment of Tg mice clearly reduced
CP-induced acute tubular necrosis (ATN; Figure 2d). ATN
scores21,22 are presented in Figure 2e. No morphological
change was found in Bz-treated Tg and WT animals, which
were designated as control.
Tubular apoptosis was compared using a well-established
early apoptosis indicator, single-stranded DNA (ssDNA)
positivity,23,24 where the tubular cell count per visual field,
the apoptosis index, was used for quantitative analyses
(Figure 3). The apoptosis index was clearly attenuated in
BzþCP-treated Tg mice, although many ssDNA-positive
cells were observed in dilated tubular nuclei and detached
tubular cells in BzþCP-treated WT, CP-treated WT, and
CP-treated Tg mice.
Immunohistochemistry of kidney tissue of hL-FABP Tg mice
at 72 h after CP or saline administration
No positive immunoreactivity to hL-FABP was found in
kidney tissue obtained from WT mice (Figure 4a, d, g, and j).
Saline-treated hL-FABP Tg animals showed strong positive
staining primarily in the cytoplasm of early (S1 and S2)
segments of the proximal tubules and the epithelium of
Bowman’s capsule (Figure 4c). Moreover, almost all proximal
tubular cells showed markedly enhanced positive staining for
hL-FABP in Bz-fed Tg mice (Figure 4e and f). Both the
Bz- and saline-treated mice showed cytoplasmic dominant
enhancement of early segments of the proximal tubules. In
Tg kidneys 72 h after CP administration, the nuclear
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Figure 3 |Apoptosis index by ssDNA staining. The ssDNA-
stained representative kidney morphology is shown. CP-exposed
kidneys were obtained from (a) WT and (b) Tg mice. Those
pretreated with Bz (abbreviated as BzþCP) were obtained from
(c) WT and (d) Tg. Bar¼ 50mm. (e) The apoptosis index was
defined as a group average score of ssDNA-positive tubular cells
per  200 visual field taken from five non-overlapping visual
fields per mouse. Although the apoptosis index of CP- and
BzþCP-treated WT mice and CP-treated Tg mice at 72 h after CP
administration was equally prominent, that of BzþCP-treated Tg
mice was significantly lower than the other groups (*Po0.05).
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Figure 2 |Morphological analysis of kidney at 72 h after CP
administration. The periodic acid-Schiff-stained representative
kidney morphology is shown. CP-exposed kidneys were obtained
from (a) WT and (b) Tg mice. Those pretreated with Bz
(abbreviated as BzþCP) were obtained from (c) WT and (d) Tg
mice. Although CP- and BzþCP-treated WT and CP-treated Tg
animals showed severe tubular damage, BzþCP-treated Tg mice
showed remarkable attenuation of tubular damage such as
epithelial detachment, dilatation, cast formation, brush-border
loss, and the presence of toxic granules (bar¼ 500 mm).
(e) Quantitative evaluation of morphologic kidney damage of Tg
and WT mice at 72 h after saline or CP administration. ATN scores
are expressed as the total of relative severity in each parameter on
a scale of 0–2 and represent mean±s.e.m. of kidney sections from
at least seven mice for each experimental condition. Each
morphological parameter was scored according to proximal
tubule necrosis, brush-border loss, cast formation, tubule
dilatation, and tubular degeneration. Statistically significant
differences (*Po0.05) were indicated when BzþCP group data
were compared with data of the CP-alone group.
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dominant pattern of hL-FABP staining was apparent in early
segments of proximal tubules and the epithelium of
Bowman’s capsule (Figure 4i). Some primarily cytoplasmic
staining in proximal tubules was also observed in the deep
cortex in these CP-treated animals. In the kidneys of
CP-treated Tg mice that had been fed Bz, both nuclear
staining and cytoplasmic staining were enhanced in the deep
cortex as well as in the early segments of proximal tubules
(Figure 4k and l). Glomeruli and distal nephron segments
were virtually negative. The CP-treated Tg kidneys both with
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Figure 4 | Immunohistochemistry of hL-FABP staining in kidney at 72 h after CP or saline administration. Middle column
demonstrates lower magnification of histology derived from Tg mice. Right column demonstrates those of higher magnification
(bar¼ 250 mm). (a, d, g, j) All of WT groups were negative for hL-FABP protein. Compared to (b, c) control Tg mice kidneys, cytoplasmic
staining of hL-FABP in proximal tubules was enhanced in (e, f) Bz-treated mice kidneys. hL-FABP expression (h, i) in CP-treated mice kidney
was clearly more prominent than the control Tg mice kidney 72 h after CP exposure, but this expression in detached or dilated proximal
tubules in (h, i) CP-treated mice was decreased or absent. (k, l) The upregulation of hL-FABP was preserved in BzþCP-treated mice kidney.
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and without Bz feeding showed almost intact tubules and
immunoreactive enhancement of hL-FABP protein when
kidneys were immunostained 24 h after CP exposure
(Figure 5). In kidneys of CP-treated Tg mice that had been
pre-fed with Bz (Figure 5b and d), cytoplasmic dominant
patterns in proximal tubular cells were more prominent and
stronger than those in CP kidneys (Figure 5a and c). The
preservation of proximal tubules 72 h after CP exposure was
parallel to the level of tubular expression of hL-FABP protein
in both groups (Figure 5c and d). However, the immunor-
eactivity of hL-FABP was diminished (Figure 5c, asterisks) or
undetectable in damaged proximal tubular cells.
Western blot analysis of kidney tissue of hL-FABP Tg mice
Using whole kidney lysate, western blot analysis of hL-FABP
protein was performed. Kidneys obtained from Tg mice that
had been fed Bz showed significantly higher hL-FABP
compared to those in control animals. The BzþCP-treated
Tg mice showed a remarkably higher hL-FABP 24 h after CP
administration compared to controls (Figure 6a and b). In
contrast, CP-treated Tg mice without Bz 24 h after CP
administration showed almost equal expression of hL-FABP
compared to controls. Western blot analysis revealed a
decrease of hL-FABP expression in CP-AKI, compared to
that of 24 h, when kidneys were obtained 72 h after CP
exposure. hL-FABP expression remained constant in animals
with CP-AKI that had been pre-fed with Bz. No signal existed
of hL-FABP in any WT group. These observations are
comparable to those related to immunohistochemistry.
Quantitative real-time reverse transcriptase-PCR analysis of
kidney tissue of hL-FABP Tg mice
Figure 7 presents the results of quantitative real-time reverse
transcriptase-PCR analysis of renal hL-FABP mRNA
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Figure 5 | Immunohistochemistry of hL-FABP staining in Tg
mice kidney at 24 and 72h after CP administration.
Representative Tg kidney sections obtained from animals
subjected to four experimental conditions: (a) CP-treated at 24 h,
(b) BzþCP-treated at 24 h, (c) CP-treated at 72 h, and (d) BzþCP-
treated at 72 h. Those were stained with anti-hL-FABP antibody, as
described in Materials and Methods. (c) In damaged tubules
depicted as asterisks, hL-FABP-positive cells were fewer or non-
existent. These findings are thought to indicate that hL-FABP in
proximal tubules is not only a stress-responsive protein but also a
viability-expressing marker (bar¼ 50 mm).
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Figure 6 |Western blot analysis of renal hL-FABP protein.
(a) Representative western blot analysis of hL-FABP. Kidneys were
harvested at 72 h after starting experiments. All groups of WT
mice were negative. (b) Fold increase of renal hL-FABP protein
corrected using actin. Statistically significant differences (*Po0.05,
**Po0.01) were indicated when the CP -alone group and BzþCP
group were compared, respectively, to the control group.
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Figure 7 |Quantitative analysis of renal L-FABP mRNA. The
fold increase of the renal expression ratio as hL-FABP mRNA/18S
rRNA (ribosomal RNA) was quantified using quantitative real-time
reverse transcriptase-PCR analysis. Statistically significant
differences (*Po0.05, **Po0.01) were indicated when the
CP-alone group and BzþCP group were compared to the
control and Bz groups, respectively.
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corrected using 18S ribosomal RNA. The Bz-pretreated Tg
mice without CP showed a 5.2-fold increase in renal
hL-FABP mRNA compared to control Tg mice. When Tg
animals received CP, hL-FABP mRNA increased 1.7-fold over
that of control Tg animals at 24 h after CP exposure. It was
much higher at 72 h, corresponding to an 81.1-fold increase
over the level shown by the control Tg group. In CP-treated
Tg mice that had been fed Bz, the increase in the renal
transcription level of hL-FABP was 34.7-fold at 24 h and
88.3-fold at 72 h compared to control animals. These levels
also corresponded to levels that were 6.6- and 16.9-fold
higher at 24 and 72 h, respectively, than that of Bz-treated
mice without CP. The renal hL-FABP transcription level in
CP-treated Tg mice that had been fed Bz at 24 h after CP
exposure was significantly increased to 21.3-fold over that of
CP-treated Tg mice at 24 h. In brief, CP promoted the
upregulation of renal hL-FABP transcription. Demonstrably,
Bz promoted this upregulation not only in normal conditions
but also in the CP-treated condition in earlier phases.
Effect of CP and fibrate on urinary shedding of hL-FABP
Bz was expected to increase the level of urinary hL-FABP in
Tg mice. Admittedly, the urinary hL-FABP level of the
Bz-treated Tg group (n¼ 7) increased approximately eight-
fold compared to control Tg animals (n¼ 7; 102.0±37.1 and
13.7±5.6 mg per g urine creatinine, respectively, Po0.05;
Figure 8). The CP-treated Tg mice at 24 h after CP exposure
showed a greater than 100-fold increase of urinary hL-FABP
excretion (1334.9±220.3) compared to that of the serially
collected timed-control specimens (Po0.05, n¼ 13), and
demonstrated a time-dependent increase (Figure 8; please
note that the scale of the vertical bar is different between
Figure 8a and b). In contrast, CP-treated Tg mice that had
been fed Bz showed a maximum increase of urinary hL-FABP
at 24 h (1548.4±363.0) compared to the timed-control
specimens (n¼ 12); the level showed decreases at 48 and
72 h. In addition, CP-treated Tg mice fed with Bz showed
significant attenuation of urinary hL-FABP compared to CP-
treated Tg mice without Bz at the time point of 48 h
(BzþCP, 1525.5±261.9; CP, 4726.1±545.0, Po0.05) and
72 h (BzþCP, 966.2±242.6; CP, 8797.2±1015.1, Po0.05).
Effect of CP and fibrate on plasma hL-FABP
The plasma hL-FABP level of Bz-treated Tg mice (Figure 9a)
was 17-fold greater than that of control animals (99.9±22.2
and 5.8±2.0 ng ml1, respectively, Po0.05). Although the
plasma hL-FABP level of both CP-treated Tg mice fed and
not fed Bz increased in a time-dependent manner, the change
in CP-treated Tg mice that had not been fed Bz was much
greater: 24 h, 18.3±11.9; 72 h, 133.6±53.2. These levels
corresponded, respectively, to 3.2- and 23-fold increases over
the mean plasma level in the control Tg group (Figure 9b).
However, minimal levels were found in CP-treated Tg mice
that were fed Bz: 24 h, 120.7±44.6; 72 h, 133.9±34.2. These
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Figure 8 | Time course of urinary hL-FABP in Tg mice. (a) Time
course of urinary hL-FABP in control and Bz groups. Statistically
significant differences (#Po0.05) were indicated when the Bz
group was compared to the control Tg group at the same time
point. (b) Time course of urinary hL-FABP in CP-alone and BzþCP
groups. Both CP- and BzþCP-treated mice displayed extremely
high levels of urinary hL-FABP at 24 h after CP administration
compared to those before CP administration. Although CP-treated
mice showed a significant increase in the urinary hL-FABP level in
a time-dependent manner, BzþCP-treated mice showed a time-
dependent decrease at 48 and 72 h. Statistically significant
differences (#Po0.05) were indicated when the BzþCP group was
compared to the CP-treated Tg group at the same time point.
Statistically significant differences (*Po0.05, **Po0.01) in serially
sampled urine were indicated for the CP -alone and BzþCP
groups.
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Figure 9 |Plasma hL-FABP levels and fold increase of plasma
and urinary hL-FABP in Tg mice. (a) Plasma hL-FABP levels in Tg
mice. Statistically significant differences (*Po0.05) were indicated
compared to the control Tg group. (b) Fold increase of plasma
hL-FABP in Tg mice compared to the basal level. (c) Fold increase
of urinary hL-FABP in Tg mice compared to the basal level.
Statistically significant differences (*Po0.05, **Po0.01) were
indicated when the BzþCP group was compared to the
CP-treated Tg group.
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levels corresponded, respectively, to 1.2- and 1.3-fold
increases compared to the mean plasma levels at those time
points in Bz-treated Tg mice without CP. The fold increase of
urinary hL-FABP shedding in serially sampled urine in
CP-treated Tg mice without Bz was significantly larger
compared to that of CP-treated Tg mice fed with Bz at 24 and
72 h after CP exposure (Figure 9c). The level was quite high
as early as 24 h after CP exposure (CP, 139.2±30.9; BzþCP,
42.8±15.0; Po0.05) compared to the basal levels of serially
sampled urine. The difference between fold increases of
plasma and urinary hL-FABP was already apparent in an
earlier phase of CP-AKI, where even BUN was equivalent to
the basal level. Therefore, as a sensitive AKI biomarker, the
monitoring of urinary hL-FABP was inferred to be clearly
superior to monitoring plasma concentration. At the same
time, urinary N-acetyl-b-D-glucosaminidase (NAG) levels in
both CP-treated Tg mice fed and not fed Bz were not
significantly changed through 72 h after CP administration,
as compared to the basal level (44.9±3.8 and 45.9±4.4 U per
g Cre, respectively). A recent study also suggested that
urinary NAG was insensitive to detect CP-AKI within 72 h, at
least in a mice model.25
Tubular accumulation of lipid and toxic lipid peroxidation
products
Next, CP-induced disorder of lipid metabolism was examined
in CP-treated kidneys. Sudan III staining was used for kidney
sections at 72 h after CP administration, revealing numerous
red lipid droplets in the cytoplasmic region of early segments
of the proximal tubules in CP-treated WT (Figure 10a) and
Tg (Figure 10b) kidney. In addition, lipid accumulation was
rarely detected in kidneys of CP-treated Tg mice that had
been fed Bz (Figure 10d), but not detected in CP-treated WT
mice fed with Bz (Figure 10c). The staining was almost
undetectable in the kidney obtained from control and
Bz-treated mice without CP (data not shown). Glomeruli
and medulla were negative for Sudan III staining.
Similarly, CP-treated WT mice, CP-treated Tg mice fed no
Bz, and CP-treated WT mice fed Bz showed massive
accumulation of 4-hydroxy-2-hexenal (HHE) in their
kidneys: HHE, as well as 4-hydroxy-nonenal, is a highly
toxic aldehyde generated during lipid peroxidation. We have
recently reported the presence of HHE in AKI kidney,
especially after ischemia–reperfusion injury;26 HHE was again
detected in CP-AKI kidney (Figure 11a). However, no such
accumulation was observed in the kidneys of CP-treated Tg
mice that had been fed Bz (Figure 11b). This finding
supported that of western blot analysis derived from whole
kidney lysate (Figure 11c). Localization of HHE was limited
in damaged tubules in early segments of the proximal
tubules. The hL-FABP-positive tubules were inferred to have
been preserved and have escaped from HHE accumulation.
Based on these results, pretreatment with Bz reduced CP-
induced tubular accumulation of lipid and lipid peroxidation
products almost completely through the upregulation of
tubular L-FABP.
DISCUSSION
The results of this study show that CP at a dose of 20 mg kg1
induced severe AKI, a result that was confirmed by measuring
histological findings and ATN scoring; BUN increased greatly
to around 150 mg per 100 ml in both WT and Tg mice by 72 h
after CP injection. Moreover, histological deterioration of
CP-induced AKI in WT was comparable to that of Tg.
TgWT
Bz
+C
P
CP
a b
c d
Figure 10 | Sudan III staining in kidney of CP-alone and
BzþCP-treated WT and Tg mice at 72 h after CP
administration. Although tubular lipid accumulation of (a) CP-
treated and (c) BzþCP-treated WT and (b) CP-treated Tg mice at
72 h after CP administration was similarly prominent, (d) BzþCP-
treated Tg mice showed almost no droplet of lipid compared to
those of other CP-treated animals (bar¼ 50mm).
HHE
Actin
Cont Bz CP Bz+CP
a b
c
Figure 11 |Double immunohistochemical staining of HHE and
hL-FABP in Tg mouse kidney and western blot analysis of
HHE. Representative images showing stained HHE and hL-FABP
in (a) CP-treated Tg kidney and (b) BzþCP-treated Tg kidney.
(c) Representative image of western blot analysis of HHE.
CP-treated Tg mice exhibited severe accumulation of HHE in
damaged tubules, whereas this accumulation was virtually absent
in BzþCP-treated kidney (bar¼ 50 mm). These findings were also
verified using western blot analysis with whole kidney lysate.
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Pretreatment with Bz in WT animals was not effective in
reducing CP-induced AKI in terms of BUN and histological
findings. Pretreatment with Bz in Tg animals was shown to
ameliorate CP-induced AKI in this study. Yamamoto et al.8
recently reported reduced susceptibility of ischemia–reperfusion
injury in Tg mice compared to that of WT mice, in which
renal hL-FABP expression played a pivotal role in the
amelioration of AKI. Therefore, we believe that a sufficient
amount of expression of renal hL-FABP is needed to
ameliorate CP-mediated AKI.
The renal transcription level of L-FABP and protein
expression in Tg mice treated with CPþBz at 24 h after CP
exposure were increased much more than those without Bz,
although urinary L-FABP levels in those two groups were
almost equivalent. Immunohistochemical analysis demon-
strated cytosolic staining of hL-FABP in control animals.
However, kidney tissue obtained from CP-treated Tg mice
showed remarkable brush-border loss and lumen dilatation,
and cytosolic immunoreactivity of hL-FABP had virtually
disappeared. The Bz pretreatment showed its efficacy in
improving those findings. Because CP inhibits genomic
replication via its binding to a DNA double strand, the
transcription level of hL-FABP will be affected by CP. The
initial shedding of urinary hL-FABP in CP-AKI will be
dependent on proximal tubular cytosolic protein, as recently
discussed in ischemia–reperfusion injury.8 In ischemia–
reperfusion, the transcription level was higher 15 h later.
The recovery of transcription level is necessary for reduction
of renal injury in CP-AKI, and pretreatment using Bz is
valuable. The cytosolic depletion of hL-FABP seen in CP-
treated kidney of Tg mice presumably degrades tubular
viability and promotes apoptosis based on the malfunction in
handling the lipid metabolism and coping with lipid
peroxidation, as presented in this study. Proximal tubular
cells might overcome CP-AKI through preservation of the
balance between cytosolic L-FABP as a fatty acid transporter
and a toxic lipid peroxidation product such as HHE.
Recently, we have confirmed that increased shedding of
urinary L-FABP is an early biomarker of AKI not only in the
CP model of AKI in mice but also during ischemia–reperfu-
sion in patients undergoing cardiac surgery.27 The rapid
translocation of hL-FABP to the nuclear compartment is
likely related to a post-translational modification of L-FABP
and induced by CP. Admittedly, despite the massive
translocation of L-FABP into the urine in the early phase
of CP-AKI and the significant attenuation of renal dysfunc-
tion and morphological damage, the Bz-mediated renal
upregulation of L-FABP was approximately 1.5-fold in CP-
treated Tg kidneys with Bz, compared to those without Bz,
when kidneys were obtained 24 h later. Further studies are
needed to understand the mechanism(s) of increased
shedding of renal hL-FABP during proximal tubular injury.
In a previous study, Portilla and co-workers reported that
the inhibition of peroxisomal and mitochondrial fatty acid
oxidation observed in kidney tissue of mice undergoing
ischemia–reperfusion AKI and CP-induced AKI results from
the reduced activity of PPAR.12–14,28–33 The results of this
study support these findings because the renal upregulation
of hL-FABP mRNA by Bz only showed efficacy in amelio-
rating CP-AKI in Tg mice. As a matter of fact, the peroxisome
proliferator response element exists in the promoter region of
hL-FABP; it therefore played a crucial role in fatty acid
oxidation in the proximal tubules. Because CP is an
antitumor drug and the lethal dosage was administered in
this study, the toxic effects of CP aside from nephrotoxicity
might affect the urine level of hL-FABP in CP-AKI. Increased
circulating L-FABP mediated by Bz might also increase
megalin-mediated endocytosis of L-FABP from the urine
space after filtration.34–37 It is plausible that enhancement of
cytosolic L-FABP expression in the proximal tubules was
derived not only from itself but also from increased filtration
of circulating L-FABP, which contributed to amelioration of
CP-induced AKI. In this study, the plasma level of hL-FABP
was increased to a significant level at 24 h after CP
administration, and it increased further until 72 h. The basal
level of plasma L-FABP had already increased compared to
that without Bz when animals were pretreated with Bz.
Moreover, CP administration increased plasma hL-FABP
but not to a significant level. It remained at that same level
until 72 h.
We next standardized the level of increase by the basal
level of control or Bz, and expressed it as a fold increase, as
presented in Figure 9. Compared to the fold increase in
plasma hL-FABP at 24 h, the fold increase of urine hL-FABP
at 24 h in CP was enormous: 3.2-fold in plasma versus 139-
fold in urine. The fold increases at 24 h were 1.2-fold in
plasma (Figure 9b) and 43-fold in urine (Figure 9c) when
animals were pretreated with Bz. Because the L-FABP coding
gene has peroxisome proliferator response element in its
promoter region, as described above, the pretreatment using
a PPAR ligand such as Bz potentially elevated plasma L-FABP
through the liver, intestine, and renal upregulation of L-FABP
transcription in Tg mice. The significant increase of plasma
L-FABP that was found for CP-treated Tg mice between 24
and 72 h might be influenced not only by the CP-induced
renal upregulation of L-FABP but also by the decrease of the
glomerular filtration rate and/or tubular reabsorption
capabilities. However, it is noteworthy that the increased
levels of urinary L-FABP 24 h later in CP-treated Tg mice fed
and not fed Bz were very much larger than those of plasma
L-FABP at the same time point. In addition, C57BL/6 WT
mice pretreated with Bz showed no improvement in renal
function, morphological damage, or lipid accumulation
induced by CP, even though it was thought to increase
circulating mouse L-FABP derived from the liver and/or
intestine. Consequently, at least in the AKI model used in this
study, the urinary hL-FABP level in Tg mice is seemingly not
parallel to the circulating plasma hL-FABP level, and is rather
defined by the transcription level of the renal proximal
tubules.
Based on these data, the efficacy of urine hL-FABP as a
biomarker of CP-AKI is readily apparent because the increase
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of urine hL-FABP was earlier than that of BUN. In fact, BUN
at 24 h after CP injection remained around 25 mg kg1 in
both WT and Tg animals. At the 24 h time point, it was
difficult to foretell the huge increase of BUN seen at 72 h and
later, but urine L-FABP increased remarkably by 24 h after CP
injection. Urine L-FABP was increased within the first 2 h
after CP administration (data not shown).
The hL-FABP Tg mice are also sensitive to a wide variety
of AKI such as ischemia–reperfusion,8 radio-contrast
media,38 cyclooxygenase-2 inhibitors,39 and aminoglycosides
(unpublished data). For this reason, these ‘humanized’ mice
are presumably useful for purposes of nephrotoxicity
validation during drug development.
In summary, CP-AKI was ameliorated by the PPAR
agonist Bz in Tg mice. This efficacy was, in part, mediated
by increased renal expression of L-FABP. Reduction of
lipotoxicity and apoptosis in renal tubules contributed to
that amelioration. Urine L-FABP was an earlier indicator of
CP-AKI when compared to BUN and thus proved itself to be
a useful early biomarker for the detection of drug-induced
nephrotoxicity.
MATERIALS AND METHODS
Animals
The engineering of hL-FABP chromosomal Tg mice is detailed
elsewhere.8 This Tg mice strain is not forcibly overexpressing.
Briefly, the genomic DNA of hL-FABP, including its promoter region
(13 kb), was microinjected into fertilized eggs obtained from C57BL/6
and CBA mice; ICR mice were used as transfected egg recipients.
The resultant Tg mice were backcrossed for more than nine
generations onto C57BL/6 mice to obtain congenic mutant mice on
an inbred background. Only heterozygous L-FABP Tg mice were
used in this experiment. Male WT and L-FABP Tg mice weighing
25–35 g were allowed food and water ad libitum.
Experimental model
Male WT and hL-FABP Tg mice were divided at random into four
groups, kept in glass-shielded metabolic cages (Metabolica;
Sugiyamagen, Tokyo, Japan), and fed with a standard chow diet or
with a special diet containing Bz (0.5% wt/wt, generously provided
by Kissei Pharmaceutical Co. Ltd, Matsumoto, Japan) for 7 days
before the induction of acute renal failure. CP (generously provided
by Nippon Kayaku Co. Ltd, Tokyo, Japan) or saline was
administered using a single intraperitoneal injection of 20 mg per
kg body weight. Immediately before and after injection of CP, blood
and urine were serially collected at each 24 h interval. Mice were
killed at 72 h after intraperitoneal injection, and kidneys were
harvested for reverse transcriptase-PCR, western blot analysis, and
immunohistological analysis. In a separate procedure, Tg kidney
specimens were similarly collected at 24 h after CP injection.
All experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals (US Department
of Health and Human Services, Public Health Services, National
Institutes of Health, NIH publication no. 86-23, 1985).
Measurement of BUN
BUN was measured by the urease–indophenol method with Urea NB
(Wako Pure Chemical Industries Ltd, Osaka, Japan), using an
absorbance 96-well plate reader (SpectraMAX Plus; Molecular
Devices Corp., Sunnyvale, CA, USA) at a wavelength of 570 nm.
Measurement of urinary creatinine
Urinary creatinine was measured using the colorimetric method
based on hydrogen peroxide measurement (Nescoat VLII CRE;
Alfresa Pharma Corp., Osaka, Japan), using the absorbance 96-well
plate reader (Molecular Devices Corp.) loaded with a 546 and
660 nm filter.
Measurement of NAG
Urinary NAG was measured using a test (NAG Rate Test Shionogi;
Shionogi & Co. Ltd, Osaka, Japan) that applied the colorimetric
method based on free chlorophenol red measurement by hydrolysis,
by which NAG reacts as sodio-3,30-dichlorophenol-sulfonphthalei-
nyl NAG, using the absorbance 96-well plate reader (Molecular
Devices Corp.) with a 575 nm filter.
Measurement of urinary and plasma hL-FABP by
enzyme-linked immunosorbent assay
Urinary hL-FABP was measured using a sandwich enzyme-linked
immunosorbent assay kit (CMIC Co. Ltd, Tokyo, Japan) following
the manufacturer’s protocol. The coefficient of variation for the
obtained value was within 10% when intra-assay reproducibility was
determined using the same sample eight times. The measurable
range of this kit is 4–400 ng ml1. This assay system does not detect
rodents’ L-FABP, particularly that derived from WT mice. Urinary
hL-FABP was expressed as the ratio of the urinary L-FABP in
micrograms to the urinary creatinine.
Morphologic evaluation of kidneys
Formalin-fixed sections were stained with hematoxylin–eosin and
periodic acid-Schiff. Morphological evaluation was performed using
well-established criteria as the ATN score in a blind manner.
Immunohistochemical analyses
Immunohistochemical staining of 2 mm paraffin sections was
performed using an indirect immunohistochemical technique. After
deparaffinization, the nonspecific reaction for horseradish per-
oxidase was blocked using 3% hydrogen peroxide in methyl alcohol
for 5 min.
Specimens were blocked initially using the mouse IgG blocking
reagent (MOM; Vector Laboratories Inc., Burlingame, CA, USA) for
immunohistochemical staining with mice monoclonal antibodies
and by using rabbit IgG (DakoCytomation, Glostrup, Denmark) for
rabbit polyclonal antibody. A primary monoclonal antibody of
hL-FABP, which is not cross-reacting to mouse L-FABP, was applied
to sections with 1:500 dilution and incubated for 1 h at room
temperature. A primary polyclonal rabbit anti-ssDNA antibody
(DakoCytomation) or monoclonal anti-HHE antibody (NOF Corp.,
Tokyo, Japan) with 1:100 dilutions was applied to sections and
incubated for 2 h at room temperature. The subsequent procedure
of sections was followed using a Vectorstain ABC system (Vector
Laboratories Inc.), according to the manufacturer’s protocol. For the
substrate–chromogen reaction, diaminobenzidine tetrahydrochlor-
ide (Simple Stain DAB; Nichiei, Tokyo, Japan) was used, according
to the manufacturer’s protocol. Control sections were subjected to
secondary antibody only (blank).
The antigen retrieval procedure by microwave was necessary for
double staining with hL-FABP and HHE. The colorimetric detection
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of HHE antibody was conducted using a combination of anti-mouse
IgG-AP secondary antibody (F Hoffman-La Roche Ltd/Roche, Basel,
Switzerland), nitro blue tetrazolium chloride/5-bromo-4-chloro-3-
indolyl phosphate, and toluidine salt solution (Roche). These
sections were counterstained by methyl green (Vector Laboratories
Inc.). Immunohistochemical examinations were made using light
microscopy (E600; Nikon Corp., Tokyo, Japan). Images were
captured using a CCD camera (DXM1200; Nikon Corp.).
The level of tubular apoptosis was quantitated using the average
number of ssDNA-positive cells per field. The number of ssDNA-
positive tubular epithelial cells was determined in 10 randomly
selected non-overlapping fields at  200 magnification in each
section of the individual mouse renal cortex. The scores of respective
kidneys were averaged, and the scores of each group were further
averaged.
Sudan III staining was applied for renal lipid accumulation.
Cryostat-frozen kidney sections of 10 mm were washed in 60%
ethanol and incubated in Sudan III (Chroma-Gesellschaft Schmid
GmbH and Co., Koengen, Germany) solution saturated with 70%
ethanol at 37 1C for 1 h. After washing in 60% ethanol, these
sections were counterstained with Mayer’s hematoxylin (Vector
Laboratories Inc.).
Quantitative real-time reverse transcriptase-PCR analysis
Total RNA was extracted from the whole kidney homogenates using
Trizol (Invitrogen Corp., Carlsbad, CA, USA). QuantiTect Reverse
Transcription Kit (Qiagen Inc., Hilden, Germany) was used
according to the manufacturer’s protocol to synthesize cDNA from
total RNA. Renal transcription levels were assessed using real-time
quantitative PCR (real-time PCR) with TaqMan Universal PCR
Master Mix (Applied Biosystems, Foster City, CA, USA) and a PCR
system (Prism 7000; Applied Biosystems), according to the
manufacturer’s instructions. The respective PCR primers were
obtained (Assay-on-Demand; Applied Biosystems) as follows: hL-
FABP (assay ID: Hs00155026_m1) and 18S ribosomal RNA (assay
ID: Hs99999901_s1).
Western blot analysis
Harvested kidneys were homogenized on ice in a radioimmuno-
precipitation assay buffer with protease inhibitors. The lysates were
separated on a 10–20% gradient sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. After transferring proteins from the gel to
a polyvinylidene difluoride membrane (Amersham Biosciences
Corp., Uppsala, Sweden), western blot analysis was performed using
1:10 diluted horseradish peroxidase-labeled hL-FABP antibody or
1:500 diluted HHE antibody for 1 h at room temperature. Can Get
Signal (Toyobo Co. Ltd, Osaka, Japan) was used in antibody dilution
buffer to reduce the background level. Subsequently, the chemilu-
minescent signal labeled using ECL Plus (Amersham Biosciences
Corp.) was detected using a CCD camera system (LAS-4000mini;
Fuji Photo Film Co. Ltd, Tokyo, Japan). The membrane was then
incubated at 50 1C for 30 min in a stripping buffer to remove all
probes. The reprobing procedure was further performed with the
antibody to actin (Chemicon Co. Ltd, Temecula, CA, USA).
Statistical analysis
The results of statistical analyses are expressed as means±s.e.m.;
Po0.05 was considered significant. Differences among groups at the
same time point were examined using the Tukey–Kramer honestly
significant difference test. Differences among experimental groups at
different time points were confirmed using one-way analysis of
variance followed by the Tukey–Kramer honestly significant
difference test for individual comparison of group means.
Differences among experimental groups in serial sampling results
were compared using multiple analyses of variance, with calculations
performed using software (JMP5.1.1; SAS Institute Inc., Cary, NC,
USA).
ACKNOWLEDGMENTS
We are very grateful to Mrs Haba, Mrs Amitani, and Mr Onimaru,
who assisted us with their technical support. Part of this study was
supported by Health and Labor Sciences Research Grants for
Research on the Human Genome, grants for Tissue Engineering
Food Biotechnology (Grant no. 057100000661) from MHLW of Japan
(EN and TS), funding from the BioBank Japan Project on the
Implementation of Personalized Medicine (Grant no. 3023168), MEXT,
Japan (EN), by the Special Coordination Funds for Promoting Science
and Technologies (Grant no. 1200015), MEXT, Japan (EN), and by NIH/
NIDDK RO1-DK075976 and a VA Merit Award, USA (DP).
REFERENCES
1. Chmurzynska A. The multigene family of fatty acid-binding proteins
(FABPs): function, structure and polymorphism. J Appl Genet 2006; 47:
39–48.
2. Haunerland NH, Spener F. Fatty acid-binding proteins—insights from
genetic manipulations. Prog Lipid Res 2004; 43: 328–349.
3. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and
activation of a family of murine peroxisome proliferator-activated
receptors. Proc Natl Acad Sci USA 1994; 91: 7355–7359.
4. Zimmerman AW, Veerkamp JH. New insights into the structure and
function of fatty acid-binding proteins. Cell Mol Life Sci 2002; 59:
1096–1116.
5. Antonenkov VD, Sormunen RT, Ohlmeier S et al. Localization of a portion
of the liver isoform of fatty-acid-binding protein (L-FABP) to peroxisomes.
Biochem J 2006; 394: 475–484.
6. Bennaars-Eiden A, Higgins L, Hertzel AV et al. Covalent modification of
epithelial fatty acid-binding protein by 4-hydroxynonenal in vitro and in
vivo. Evidence for a role in antioxidant biology. J Biol Chem 2002; 277:
50693–50702.
7. Wang G, Gong Y, Anderson J et al. Antioxidative function of L-FABP in
L-FABP stably transfected Chang liver cells. Hepatology 2005; 42: 871–879.
8. Yamamoto T, Noiri E, Ono Y et al. Renal L-type fatty acid binding protein
in acute ischemic injury. J Am Soc Nephrol 2007; 18: 2894–2902.
9. Oyama Y, Takeda T, Hama H et al. Evidence for megalin-mediated
proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic
molecules. Lab Invest 2005; 85: 522–531.
10. Hishikawa K, Marumo T, Miura S et al. Musculin/MyoR is expressed in
kidney side population cells and can regulate their function. J Cell Biol
2005; 169: 921–928.
11. Yang T, Michele DE, Park J et al. Expression of peroxisomal proliferator-
activated receptors and retinoid X receptors in the kidney. Am J Physiol
1999; 277: F966–F973.
12. Li S, Basnakian A, Bhatt R et al. PPAR-alpha ligand ameliorates acute renal
failure by reducing cisplatin-induced increased expression of renal
endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990–F998.
13. Li S, Gokden N, Okusa MD et al. Anti-inflammatory effect of fibrate
protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:
F469–F480.
14. Li S, Wu P, Yarlagadda P et al. PPAR alpha ligand protects during cisplatin-
induced acute renal failure by preventing inhibition of renal FAO and
PDC activity. Am J Physiol Renal Physiol 2004; 286: F572–F580.
15. Negishi K, Noiri E, Sugaya T et al. A role of liver fatty acid-binding protein
in cisplatin-induced acute renal failure. Kidney Int 2007; 72: 348–358.
16. Simon TC, Roth KA, Gordon JI. Use of transgenic mice to map cis-acting
elements in the liver fatty acid-binding protein gene (Fabpl) that regulate
its cell lineage-specific, differentiation-dependent, and spatial patterns of
expression in the gut epithelium and in the liver acinus. J Biol Chem 1993;
268: 18345–18358.
17. Sweetser DA, Lowe JB, Gordon JI. The nucleotide sequence of the rat liver
fatty acid-binding protein gene. Evidence that exon 1 encodes an
oligopeptide domain shared by a family of proteins which bind
hydrophobic ligands. J Biol Chem 1986; 261: 5553–5561.
Kidney International (2008) 73, 1374–1384 1383
K Negishi et al.: L-FABP and bezafibrate in cisplatin-induced AKI o r ig ina l a r t i c l e
18. Kamijo A, Kimura K, Sugaya T et al. Urinary fatty acid-binding protein as a
new clinical marker of the progression of chronic renal disease. J Lab Clin
Med 2004; 143: 23–30.
19. Kamijo A, Sugaya T, Hikawa A et al. Urinary excretion of fatty acid-binding
protein reflects stress overload on the proximal tubules. Am J Pathol
2004; 165: 1243–1255.
20. Kamijo-Ikemori A, Sugaya T, Obama A et al. Liver-type fatty acid-binding
protein attenuates renal injury induced by unilateral ureteral obstruction.
Am J Pathol 2006; 169: 1107–1117.
21. Solez K, Morel-Maroger L, Sraer JD. The morphology of ‘acute tubular
necrosis’ in man: analysis of 57 renal biopsies and a comparison with the
glycerol model. Medicine (Baltimore) 1979; 58: 362–376.
22. Noiri E, Peresleni T, Miller F et al. In vivo targeting of inducible NO
synthase with oligodeoxynucleotides protects rat kidney against
ischemia. J Clin Invest 1996; 97: 2377–2383.
23. Kawarada Y, Miura N, Sugiyama T. Antibody against single-stranded DNA
useful for detecting apoptotic cells recognizes hexadeoxynucleotides
with various base sequences. J Biochem (Tokyo) 1998; 123: 492–498.
24. Naruse I, Keino H, Kawarada Y. Antibody against single-stranded DNA
detects both programmed cell death and drug-induced apoptosis.
Histochemistry 1994; 101: 73–78.
25. Mishra J, Mori K, Ma Q et al. Neutrophil gelatinase-associated lipocalin: a
novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol
2004; 24: 307–315.
26. Doi K, Suzuki Y, Nakao A et al. Radical scavenger edaravone developed for
clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney
Int 2004; 65: 1714–1723.
27. Portilla D, Dent C, Sugaya T et al. Liver fatty acid-binding protein as a biomarker
of acute kidney injury after cardiac surgery. Kidney Int 2008; 73: 465–472.
28. Portilla D. Role of fatty acid beta-oxidation and calcium-independent
phospholipase A2 in ischemic acute renal failure. Curr Opin Nephrol
Hypertens 1999; 8: 473–477.
29. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23:
432–438.
30. Portilla D, Dai G, Peters JM et al. Etomoxir-induced PPARalpha-modulated
enzymes protect during acute renal failure. Am J Physiol Renal Physiol
2000; 278: F667–F675.
31. Nagothu KK, Bhatt R, Kaushal GP et al. Fibrate prevents cisplatin-induced
proximal tubule cell death. Kidney Int 2005; 68: 2680–2693.
32. Portilla D, Dai G, McClure T et al. Alterations of PPARalpha and its
coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 2002;
62: 1208–1218.
33. Portilla D, Li S, Nagothu KK et al. Metabolomic study of cisplatin-induced
nephrotoxicity. Kidney Int 2006; 69: 2194–2204.
34. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic
receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280:
F562–F573.
35. Kozyraki R, Fyfe J, Verroust PJ et al. Megalin-dependent cubilin-mediated
endocytosis is a major pathway for the apical uptake of transferrin
in polarized epithelia. Proc Natl Acad Sci USA 2001; 98:
12491–12496.
36. Moestrup SK, Verroust PJ. Megalin- and cubilin-mediated endocytosis of
protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu
Rev Nutr 2001; 21: 407–428.
37. Zou Z, Chung B, Nguyen T et al. Linking receptor-mediated
endocytosis and cell signaling: evidence for regulated intramembrane
proteolysis of megalin in proximal tubule. J Biol Chem 2004; 279:
34302–34310.
38. Nakamura T, Sugaya T, Node K et al. Urinary excretion of liver-type fatty
acid-binding protein in contrast medium-induced nephropathy. Am J
Kidney Dis 2006; 47: 439–444.
39. Tanaka T, Noiri E, Yamamoto T et al. Urine human L-FABP is a potential
biomarker to predict COX-inhibitor induced renal injury. Nephron Exp
Nephrol 2008; 108: e19–e26.
1384 Kidney International (2008) 73, 1374–1384
or ig ina l a r t i c l e K Negishi et al.: L-FABP and bezafibrate in cisplatin-induced AKI
